Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011.
The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candidemia is common and associated with high morbidity and mortality; changes in population-based incidence rates have not been reported. METHODS: We conducted active, population-based surveillance in metropolitan Atlanta, Georgia, and Baltimore City/County, Maryland (combined population 5.2 million), during 2008-2011. We calculated candidemia incidence and antifungal drug resistance compared with prior surveillance (Atlanta, 1992-1993; Baltimore, 1998-2000). RESULTS: We identified 2675 cases of candidemia with 2329 isolates during 3 years of surveillance. Mean annual crude incidence per 100 000 person-years was 13.3 in Atlanta and 26.2 in Baltimore. Rates were highest among adults aged ≥65 years (Atlanta, 59.1; Baltimore, 72.4) and infants (aged <1 year; Atlanta, 34.3; Baltimore, 46.2). In both locations compared with prior surveillance, adjusted incidence significantly declined for infants of both black and white race (Atlanta: black risk ratio [RR], 0.26 [95% confidence interval {CI}, .17-.38]; white RR: 0.19 [95% CI, .12-.29]; Baltimore: black RR, 0.38 [95% CI, .22-.64]; white RR: 0.51 [95% CI: .29-.90]). Prevalence of fluconazole resistance (7%) was unchanged compared with prior surveillance; 32 (1%) isolates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant to both fluconazole and an echinocandin. CONCLUSIONS: We describe marked shifts in candidemia epidemiology over the past 2 decades. Adults aged ≥65 years replaced infants as the highest incidence group; adjusted incidence has declined significantly in infants. Use of antifungal prophylaxis, improvements in infection control, or changes in catheter insertion practices may be contributing to these declines. Further surveillance for antifungal resistance and efforts to determine effective prevention strategies are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All-cause in-hospital mortality of candidemia has been reported as high as 36% in the US.27,51,52”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [51]
In the citing paper
“Candidemia is one of the most common health care–associated BSIs in the United States, with all-cause in-hospital mortality of up to 30%.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“In population-based surveillance performed in the metropolitan areas of Atlanta, Georgia, and Baltimore, Maryland, candidemia incidence (primarily among adults) increased 10%–40% from the early 1990s and the late 2000s, which was followed by more recent reports of decreases in these areas (6,28–30).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“This contrasts with data from the early 1990s, when infants had the highest incidence (6), followed by substantial decreases by the late 2000s (26,28).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“The previously reported racial disparity in candidemia persisted in this surveillance period (6), with a 2.3 times higher incidence among blacks than among nonblacks.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198 · cited 1×
“%) met criteria for sepsis [19].”
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candida species are among the most common causes of BSIs and are associated with high morbidity and mortality, as well as increases in hospital cost and length of stay [1–5].”
An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU
Pronovost, P., Needham, D., Berenholtz, S., Sinopoli, D., Chu, H., Cosgrove, S., Sexton, B., Hyzy, R., Welsh, R., Roth, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061115 · Cited by 4,387 · cited 2×
“…dramatic declines in some central line– associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus , following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida species [20, 24, 34–36].”
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“shown to decrease risk of disease [21, 25–29].”
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309 · cited 1×
“Increases in common risk factors such as diabetes [30], ICU admissions [31, 32], or numbers of patients receiving immunosuppressive therapies [33] may have resulted in increases in the overall pool of patients at high risk for candidemia.”
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“0 %) between centres [2, 14, 18, 31] possibly because of lack of standardized criteria.”
Systematic Reviews of Diagnostic Test Accuracy
Leeflang, M. M. G., Deeks, J. J., Gatsonis, C., & Bossuyt, P. M. M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-12-200812160-00008 · Cited by 1,124 · cited 1×
“albicans species has been well documented [20, 37–42].”
Pappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845 · cited 8×
“Other severity scores like SAPS II and SOFA, central venous catheterization, corticosteroid therapy, total parenteral nutrition, antibiotic use, sepsis/ shock and antifungal treatment are common predictors [15–18, 33].”
InfluentialHalpern, N. A., & Pastores, S. M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b090d0 · Cited by 817 · cited 2×
“001); C. glabrata was most frequently isolated in this group (n = 45 [40% of all species found in CO patients]), followed by Candida albicans (n = 36 [32”
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784 · cited 1×
“Candida species are among the most common causes of BSIs and are associated with high morbidity and mortality, as well as increases in hospital cost and length of stay [1–5].”
Trends in the postmortem epidemiology of invasive fungal infections at a University Hospital
Groll, A. H., Shah, P. M., Mentzel, C., Schneider, M., Just-Nuebling, G., & Huebner, K. (1996) · Journal of Infection · doi:10.1016/s0163-4453(96)92700-0 · Cited by 778
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758
Pfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694 · cited 1×
“Over the past decade, Candida species with reduced fluconazole susceptibility, such as Candida glabrata , have become more prevalent in some patient populations [8–12].”
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
León, C., Ruiz-Santana, S., Saavedra, P., Almirante, B., Nolla-Salas, J., Álvarez-Lerma, F., Garnacho-Montero, J., & León, M. Á. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000202208.37364.7d · Cited by 659
Parczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649 · cited 4×
“Neonates and infants have historically been populations with some of the highest rates of candidemia [3, 6, 7, 20–23].”
InfluentialSelf-citationOdabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R. J., Ketchum, P. A., Finkelman, M. A., Rex, J. H., & Ostrosky-Zeichner, L. (2004) · Clinical Infectious Diseases · doi:10.1086/421944 · Cited by 642
-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis
Karageorgopoulos, D. E., Vouloumanou, E. K., Ntziora, F., Michalopoulos, A., Rafailidis, P. I., & Falagas, M. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq206 · Cited by 538
Leroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819efac0 · Cited by 535 · cited 10×
“Where comparisons were made to previous surveillance data [6, 7] the new breakpoints were applied to the old data [16], and thus resistance reported here differs from resistance previously reported.”
InfluentialRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457 · cited 5×
“Where comparisons were made to previous surveillance data [6, 7] the new breakpoints were applied to the old data [16], and thus resistance reported here differs from resistance previously reported.”
InfluentialMorgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437
Self-citationDetection of a wide range of medically important fungi by the polymerase chain reaction
Makimura, K., Murayama, S. Y., & Yamaguchi, H. (1994) · Journal of Medical Microbiology · doi:10.1099/00222615-40-5-358 · Cited by 408
Hepatic Candidiasis in Cancer Patients: The Evolving Picture of the Syndrome
THALER, M., PASTAKIA, B., SHAWKER, T. H., O'LEARY, T., & PIZZO, P. A. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-1-88 · Cited by 395
Kett, D. H., Azoulay, E., Echeverria, P. M., & Vincent, J.-L. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206c1ca · Cited by 389 · cited 10×
“blood cultures in animal models of IC [13, 18].”
InfluentialPCR Diagnosis of Invasive Candidiasis: Systematic Review and Meta-Analysis
Avni, T., Leibovici, L., & Paul, M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01602-10 · Cited by 389
Meta-analysis in Stata : an updated collection from the Stata journal
Palmer, T., & Sterne, J. A. C. (2015) · Medical Entomology and Zoology · Cited by 388
León, C., Ruiz-Santana, S., Saavedra, P., Galván, B., Blanco, A., Castro, C., Balasini, C., Utande-Vázquez, A., González de Molina, F. J., Blasco-Navalproto, M. A., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819daa14 · Cited by 375 · cited 1×
“antifungal prophylaxis has been shown to be effective in selected patient populations, there is still debate on the application of risk prediction tools [43] and other preventive strategies.”
The changing face of epidemiology of invasive fungal disease in Europe
Lass‐Flörl, C. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01691.x · Cited by 369 · cited 10×
“Where comparisons were made to previous surveillance data [6, 7] the new breakpoints were applied to the old data [16], and thus resistance reported here differs from resistance previously reported.”
InfluentialA Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates
Manzoni, P., Stolfi, I., Pugni, L., Decembrino, L., Magnani, C., Vetrano, G., Tridapalli, E., Corona, G., Giovannozzi, C., Farina, D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065733 · Cited by 356 · cited 1×
“shown to decrease risk of disease [21, 25–29].”
Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis
Mengoli, C., Cruciani, M., Barnes, R. A., Loeffler, J., & Donnelly, J. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70019-2 · Cited by 354
Falagas, M. E., Roussos, N., & Vardakas, K. Z. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.04.006 · Cited by 346
Tumbarello, M., Posteraro, B., Trecarichi, E. M., Fiori, B., Rossi, M., Porta, R., de Gaetano Donati, K., La Sorda, M., Spanu, T., Fadda, G., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00131-07 · Cited by 343
Hachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331
Schulman, J., Stricof, R., Stevens, T. P., Horgan, M., Gase, K., Holzman, I. R., Koppel, R. I., Nafday, S., Gibbs, K., Angert, R., et al. (2011) · Pediatrics · doi:10.1542/peds.2010-2873 · Cited by 316 · cited 1×
“This decline is consistent with other reports [21, 24].”
Berenguer, J., Buck, M., Witebsky, F., Stock, F., Pizzo, P. A., & Walsh, T. J. (1993) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(93)90020-8 · Cited by 290
Loeffler, J., Henke, N., Hebart, H., Schmidt, D., Hagmeyer, L., Schumacher, U., & Einsele, H. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.2.586-590.2000 · Cited by 289
Fridkin, S. K., Kaufman, D., Edwards, J. R., Shetty, S., Horan, T., & Hospitals, T. N. N. I. S. S. (2006) · Pediatrics · doi:10.1542/peds.2005-1996 · Cited by 284 · cited 2×
“Prophylaxis with fluconazole in high-risk patients, such as neonates, has been shown to decrease risk of disease [21, 25–29].”
Panfungal PCR Assay for Detection of Fungal Infection in Human Blood Specimens
Van Burik, J.-A., Myerson, D., Schreckhise, R. W., & Bowden, R. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.5.1169-1175.1998 · Cited by 278
Vital signs: central line-associated blood stream infections--United States, 2001, 2008, and 2009.
(2011) · PubMed · Cited by 278
Pfaller, M. A., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.02.016 · Cited by 274 · cited 9×
“Neonates and infants have historically been populations with some of the highest rates of candidemia [3, 6, 7, 20–23].”
InfluentialNolla-Salas, J., Sitges-Serra, A., León-Gil, C., Martínez-González, J., León-Regidor, M. A., Ibán˜ez-Lucí, P., & Torres-Rodríguez, J. M. (1997) · Intensive Care Medicine · doi:10.1007/s001340050286 · Cited by 263
Senn, L., Robinson, J. O., Schmidt, S., Knaup, M., Asahi, N., Satomura, S., Matsuura, S., Duvoisin, B., Bille, J., Calandra, T., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/527382 · Cited by 263
Klotz, S. A., Chasin, B. S., Powell, B., Gaur, N. K., & Lipke, P. N. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.07.001 · Cited by 253
Effects of nosocomial candidemia on outcomes of critically ill patients
Blot, S. I., Vandewoude, K. H., Hoste, E. A., & Colardyn, F. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01248-2 · Cited by 235 · cited 3×
“Prophylaxis with fluconazole in high-risk patients, such as neonates, has been shown to decrease risk of disease [21, 25–29].”
Parkins, M. D., Sabuda, D. M., Elsayed, S., & Laupland, K. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm212 · Cited by 229
Westh, H., Lisby, G., Breysse, F., Böddinghaus, B., Chomarat, M., Gant, V., Goglio, A., Raglio, A., Schuster, H., Stuber, F., et al. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02736.x · Cited by 228
Bassetti, M., Merelli, M., Righi, E., Diaz-Martin, A., Rosello, E. M., Luzzati, R., Parra, A., Trecarichi, E. M., Sanguinetti, M., Posteraro, B., et al. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01998-13 · Cited by 228 · cited 7×
“2 years) [2, 14].”
InfluentialNucci, M., Anaissie, E., Betts, R. F., Dupont, B. F., Wu, C., Buell, D. N., Kovanda, L., & Lortholary, O. (2010) · Clinical Infectious Diseases · doi:10.1086/653935 · Cited by 228 · cited 5×
“We did not interfere with the existing protocol of any ICU and some critical care specialists believe those studies where a lack of benefit of CVC removal was demonstrated [4, 30].”
InfluentialDiagnostic Performance of the (1→3)‐β‐ d ‐Glucan Assay for Invasive Fungal Disease
Koo, S., Bryar, J. M., Page, J. H., Baden, L. R., & Marty, F. M. (2009) · Clinical Infectious Diseases · doi:10.1086/647942 · Cited by 220
McNemar χ2test revisited: comparing sensitivity and specificity of diagnostic examinations
Trajman, A., & Luiz, R. R. (2008) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510701666031 · Cited by 218
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00160-6 · Cited by 216 · cited 1×
“Over the past decade, Candida species with reduced fluconazole susceptibility, such as Candida glabrata , have become more prevalent in some patient populations [8–12].”
Ahmad, S., Khan, Z., Mustafa, A. S., & Khan, Z. U. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.7.2483-2489.2002 · Cited by 214
Lerolle, N., Trinquart, L., Bornstain, C., Tadié, J.-M., Imbert, A., Diehl, J.-L., Fagon, J.-Y., & Guérot, E. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b088ec · Cited by 205 · cited 1×
“Increases in common risk factors such as diabetes [30], ICU admissions [31, 32], or numbers of patients receiving immunosuppressive therapies [33] may have resulted in increases in the overall pool of patients at high risk for candidemia.”
Treatment-related risk factors for hospital mortality in Candida bloodstream infections
Labelle, A. J., Micek, S. T., Roubinian, N., & Kollef, M. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b3477 · Cited by 181
Pfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.06.015 · Cited by 180 · cited 1×
“albicans species has been well documented [20, 37–42].”
Krause, D. S., Reinhardt, J., Vazquez, J. A., Reboli, A., Goldstein, B. P., Wible, M., & Henkel, T. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2021-2024.2004 · Cited by 179 · cited 1×
“albicans species has been well documented [20, 37–42].”
Active Surveillance of Candidemia, Australia
Chen, S., Slavin, M., Nguyen, Q., Marriott, D., Playford, E. G., Ellis, D., Sorrell, T., & Study, T. A. C. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1210.060389 · Cited by 174 · cited 8×
“Other severity scores like SAPS II and SOFA, central venous catheterization, corticosteroid therapy, total parenteral nutrition, antibiotic use, sepsis/ shock and antifungal treatment are common predictors [15–18, 33].”
InfluentialGuery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1338-7 · Cited by 173 · cited 5×
“Candida species are among the most common causes of BSIs and are associated with high morbidity and mortality, as well as increases in hospital cost and length of stay [1–5].”
InfluentialPCR-based diagnosis of human fungal infections
Khot, P. D., & Fredricks, D. N. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.104 · Cited by 171
Klingspor, L., & Jalal, S. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01498.x · Cited by 162 · cited 1×
“albicans species has been well documented [20, 37–42].”
Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp.
Playford, E. G., Marriott, D., Nguyen, Q., Chen, S., Ellis, D., Slavin, M., & Sorrell, T. C. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181760f42 · Cited by 156 · cited 9×
“glabrata in the Western world can be linked to increased use of azole prophylaxis [1, 11, 15, 21].”
InfluentialRisk factors for albicans and non-albicans candidemia in the intensive care unit*
Chow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D. A., Chawla, V., Young, J. A., & Hadley, S. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31816fc4cd · Cited by 154 · cited 8×
“glabrata in the Western world can be linked to increased use of azole prophylaxis [1, 11, 15, 21].”
InfluentialWhite, M. H. (1997) · Clinical Infectious Diseases · doi:10.1086/513661 · Cited by 151 · cited 2×
“This decline is consistent with other reports [21, 24].”
McMullan, R., Metwally, L., Coyle, P. V., Hedderwick, S., McCloskey, B., O'Neill, H. J., Patterson, C. C., Thompson, G., Webb, C. H., & Hay, R. J. (2008) · Clinical Infectious Diseases · doi:10.1086/528690 · Cited by 145
Polymerase Chain Reaction for the Diagnosis of Candidemia
Kan, V. L. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.3.779 · Cited by 141 · cited 2×
“Recent reports have documented significant and dramatic declines in some central line–associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus, following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida…”
Das, I., Nightingale, P., Patel, M., & Jumaa, P. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.06.006 · Cited by 137 · cited 2×
“7 %) has been reported in some studies [3, 20, 32], as compared to the present one (19.”
Multiplex polymerase chain reaction detection enhancement of bacteremia and fungemia*
Louie, R. F., Tang, Z., Albertson, T. E., Cohen, S., Tran, N. K., & Kost, G. J. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31816f487c · Cited by 133
Recent experience with fungaemia: change in species distribution and azole resistance
Chakrabarti, A., Chatterjee, S. S., Rao, K. L. N., Zameer, M. M., Shivaprakash, M. R., Singhi, S., Singh, R., & Varma, S. C. (2009) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540902777105 · Cited by 132 · cited 3×
“tropicalis [23].”
von Lilienfeld-Toal, M., Lehmann, L. E., Raadts, A. D., Hahn-Ast, C., Orlopp, K. S., Marklein, G., Purr, I., Cook, G., Hoeft, A., Glasmacher, A., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00491-09 · Cited by 132
Wahyuningsih, R., Freisleben, H.-J., Sonntag, H.-G., & Schnitzler, P. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.8.3016-3021.2000 · Cited by 131
Alam, F. F., Mustafa, A. S., & Khan, Z. U. (2007) · BMC Infectious Diseases · doi:10.1186/1471-2334-7-103 · Cited by 130
Risk Factors for Fluconazole-Resistant Candidemia
Garnacho-Montero, J., Díaz-Martín, A., García-Cabrera, E., Ruiz Pérez de Pipaón, M., Hernández-Caballero, C., Aznar-Martín, J., Cisneros, J. M., & Ortiz-Leyba, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00479-10 · Cited by 127 · cited 1×
“Over the past decade, Candida species with reduced fluconazole susceptibility, such as Candida glabrata, have become more prevalent in some patient populations [8–12].”
Candidemia in critically ill patients: difference of outcome between medical and surgical patients
Charles, P., Doise, J. M., Quenot, J., Aube, H., Dalle, F., Chavanet, P., Milési, N., Aho, S., Portier, H., & Blettery, B. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-2002-x · Cited by 121
Lau, A., Halliday, C., Chen, S. C.-A., Playford, E. G., Stanley, K., & Sorrell, T. C. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01650-09 · Cited by 118
Alexander, B. D., Smith, P. B., Davis, R. D., Perfect, J. R., & Reller, L. B. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01183-10 · Cited by 116
Rapid Detection of Candida albicans in Clinical Blood Samples by Using a TaqMan-Based PCR Assay
Maaroufi, Y., Heymans, C., Bruyne, J.-M. D., Duchateau, V., Rodriguez‐Villalobos, H., Aoun, M., & Crokaert, F. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.7.3293-3298.2003 · Cited by 115
Serum Is More Suitable than Whole Blood for Diagnosis of Systemic Candidiasis by Nested PCR
Bougnoux, M.-E., Dupont, C., Mateo, J., Saulnier, P., Faivre, V., Payen, D., & Nicolas-Chanoine, M.-H. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.925-930.1999 · Cited by 115
Detection of seven Candida species using the Light-Cycler system
White, P. L., Shetty, A., & Barnes, R. A. (2003) · Journal of Medical Microbiology · doi:10.1099/jmm.0.05049-0 · Cited by 113
Kami, M., Machida, U., Okuzumi, K., Matsumura, T., Mori, S., Hori, A., Kashima, T., Kanda, Y., Takaue, Y., Sakamaki, H., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03414.x · Cited by 111
Mohr, J. F., Sims, C., Paetznick, V., Rodriguez, J., Finkelman, M. A., Rex, J. H., & Ostrosky-Zeichner, L. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01240-10 · Cited by 110
Trick, W. E., & Fridkin, S. K. (2002) · Cited by 103
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
Garcia-Effron, G., Chua, D. J., Tomada, J. R., DiPersio, J., Perlin, D. S., Ghannoum, M., & Bonilla, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-09 · Cited by 102 · cited 1×
“The newest class of antifungal medications, the echinocandins, are considered first-line empiric therapy for candidemia, and there are reports of echinocandin-resistant invasive infection [13, 14].”
Maaroufi, Y., Ahariz, N., Husson, M., & Crokaert, F. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3159-3163.2004 · Cited by 101
Morace, G., Pagano, L., Sanguinetti, M., Posteraro, B., Mele, L., Equitani, F., D’Amore, G., Leone, G., & Fadda, G. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1871-1875.1999 · Cited by 101
Marcos, M., Soriano, À., Iñurrieta, A., Martínez, J. A., Romero, A. R., Cobos, N., Hernandez, C., Almela, M., Marco, F., & Mensa, J. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr231 · Cited by 101 · cited 1×
“as those associated with Staphylococcus aureus, following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida species [20, 24, 34–36].”
Lockhart, S. R., Messer, S. A., Gherna, M., Bishop, J. A., Merz, W. G., Pfaller, M. A., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02315-08 · Cited by 99 · cited 3×
“Prophylaxis with fluconazole in high-risk patients, such as neonates, has been shown to decrease risk of disease [21, 25–29].”
Self-citationEarly treatment of candidemia in adults: a review
Ostrosky-Zeichner, L., Kullberg, B. J., Bow, E. J., Hadley, S., León, C., Nucci, M., Patterson, T. F., & Perfect, J. R. (2011) · Medical Mycology · doi:10.3109/13693786.2010.512300 · Cited by 97 · cited 1×
“Although antifungal prophylaxis has been shown to be effective in selected patient populations, there is still debate on the application of risk prediction tools [43] and other preventive strategies.”
Leroy, G., Lambiotte, F., Thévenin, D., Lemaire, C., Parmentier, E., Devos, P., & Leroy, O. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-50 · Cited by 92 · cited 5×
“Over the past decade, Candida species with reduced fluconazole susceptibility, such as Candida glabrata, have become more prevalent in some patient populations [8–12].”
InfluentialSupplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
(2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 89
Morace, G., Sanguinetti, M., Posteraro, B., Cascio, G. L., & Fadda, G. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.667-672.1997 · Cited by 89
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Barton, R., Bijie, H., Bille, J., Chang, S.-C., da Luz Martins, M., Duse, A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.01.002 · Cited by 80 · cited 1×
“Over the past 20 years, the emergence of non– C. albicans species has been well documented [20, 37–42].”
Shetty, S. S., Harrison, L. H., Hajjeh, R. A., Taylor, T., Mirza, S. A., Schmidt, A. B., Sanza, L. T., Shutt, K. A., & Fridkin, S. K. (2005) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000168751.11375.d6 · Cited by 78 · cited 1×
“Neonates and infants have historically been populations with some of the highest rates of candidemia [3, 6, 7, 20–23].”
Self-citationAntifungal use influences Candida species distribution and susceptibility in the intensive care unit
Fournier, P., Schwebel, C., Maubon, D., Vesin, A., Lebeau, B., Foroni, L., Hamidfar-Roy, R., Cornet, M., Timsit, J.-F., & Pelloux, H. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr394 · Cited by 76 · cited 3×
“Prophylaxis with fluconazole in high-risk patients, such as neonates, has been shown to decrease risk of disease [21, 25–29].”
Detection of Fungemia by Polymerase Chain Reaction in Critically Ill Neonates and Children
Tirodker, U., Nataro, J. P., Smith, S., LasCasas, L., & Fairchild, K. D. (2003) · Journal of Perinatology · doi:10.1038/sj.jp.7210868 · Cited by 74
Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection
Klevay, M. J., Ernst, E. J., Hollanbaugh, J. L., Miller, J. G., Pfaller, M. A., & Diekema, D. J. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.10.001 · Cited by 73 · cited 2×
“Among those who did not receive antifungal treatment (n = 191 [10%]), most (n = 109 [57”
Effect of fluconazole consumption on long-term trends in candidal ecology
Blot, S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl241 · Cited by 72 · cited 3×
“Prophylaxis with fluconazole in high-risk patients, such as neonates, has been shown to decrease risk of disease [21, 25–29].”
Rapid diagnosis of candidaemia by real-time PCR detection of Candida DNA in blood samples
Wellinghausen, N., Siegel, D., Winter, J., & Gebert, S. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.007906-0 · Cited by 70
Pryce, T. M., Kay, I. D., Palladino, S., & Heath, C. H. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(03)00139-1 · Cited by 69
Antifungal Prophylaxis to Prevent Neonatal Candidiasis: A Survey of Perinatal Physician Practices
Burwell, L. A., Kaufman, D., Blakely, J., Stoll, B. J., & Fridkin, S. K. (2006) · Pediatrics · doi:10.1542/peds.2006-0446 · Cited by 69
Candidemia is Costly--Plain and Simple
Fridkin, S. K. (2005) · Clinical Infectious Diseases · doi:10.1086/496935 · Cited by 68 · cited 1×
“Neonates and infants have historically been populations with some of the highest rates of candidemia [3, 6, 7, 20–23].”
González de Molina, F. J., León, C., Ruiz-Santana, S., Saavedra, P., & the CAVA I Study Group (2012) · Critical Care · doi:10.1186/cc11388 · Cited by 66 · cited 10×
“2 years) [2, 14].”
InfluentialMoreira-Oliveira, M. S., Mikami, Y., Miyaji, M., Imai, T., Schreiber, A. Z., & Moretti, M. L. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0041-7 · Cited by 66
Lin, M., Lu, H., & Chen, W. (2001) · Clinical Infectious Diseases · doi:10.1086/322631 · Cited by 66
Evaluation of nested and real-time PCR assays in the diagnosis of candidaemia
Khlif, M., Mary, C., Sellami, H., Sellami, A., Dumon, H., Ayadi, M. A., & Ranque, S. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02762.x · Cited by 61 · cited 2×
“Recent reports have documented significant and dramatic declines in some central line–associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus, following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida…”
Kasai, M., Francesconi, A., Petraitiene, R., Petraitis, V., Kelaher, A. M., Kim, H.-S., Meletiadis, J., Sein, T., Bacher, J., & Walsh, T. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.1.143-150.2006 · Cited by 60
Fuller, D. D., Davis, T. E., Denys, G. A., & York, M. K. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.8.2933-2936.2001 · Cited by 56
Candidemia in the 21st Century
Chang, A., Neofytos, D., & Horn, D. (2008) · Future Microbiology · doi:10.2217/17460913.3.4.463 · Cited by 43 · cited 1×
“Candida species are commensals of the human gastrointestinal tract and can cause BSIs that are not the direct result of poor central line insertion practices, and instead may be more dependent on catheter maintenance after insertion [20, 22, 34] or may be unrelated to the central line.”
No increase in primary nosocomial candidemia in 682 German intensive care units during 2006 to 2011
Meyer, E., Geffers, C., Gastmeier, P., & Schwab, F. (2013) · Eurosurveillance · doi:10.2807/ese.18.24.20505-en · Cited by 42 · cited 1×
“glabrata in the Western world can be linked to increased use of azole prophylaxis [1, 11, 15, 21].”
Resolution of Discrepant Results for Candida Species Identification by Using DNA Probes
Coignard, C., Hurst, S. F., Benjamin, L. E., Brandt, M. E., Warnock, D. W., & Morrison, C. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.2.858-861.2004 · Cited by 41
Posteraro, B., Sanguinetti, M., Masucci, L., Romano, L., Morace, G., & Fadda, G. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.4.1609-1614.2000 · Cited by 40
Detection of candidemia by polymerase chain reaction
Rand, K. H., Houck, H., & Wolff, M. (1994) · Molecular and Cellular Probes · doi:10.1006/mcpr.1994.1030 · Cited by 39
Hurley, D. L., Balow, J. E., & Fauci, A. S. (1975) · Journal of Infectious Diseases · doi:10.1093/infdis/132.4.393 · Cited by 38
Khan, Z., & Mustafa, A. S. (2001) · Microbiological Research · doi:10.1078/0944-5013-00072 · Cited by 35 · cited 1×
“Recent reports have documented significant and dramatic declines in some central line–associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus, following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida…”
Fluconazole prophylaxis: can we eliminate invasive Candida infections in the neonatal ICU?
Kaufman, D. A. (2008) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3282f79c48 · Cited by 34
Candida spp. bloodstream infection: influence of antifungal treatment on outcome
Ortega, M., Marco, F., Soriano, À., Almela, M., Martínez, J. A., Pitart, C., & Mensa, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp495 · Cited by 33 · cited 1×
“Over the past decade, Candida species with reduced fluconazole susceptibility, such as Candida glabrata, have become more prevalent in some patient populations [8–12].”
Metwally, L. A., Fairley, D., Coyle, P. V., Hay, R. J., Hedderwick, S. A., McCloskey, B., O’Neill, H. J., Webb, C. H., & McMullan, R. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.2008/002444-0 · Cited by 33
Girmenia, C., Martino, P., De Bernardis, F., & Cassone, A. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.4.903-906.1997 · Cited by 32
Factors accounting for misidentification of Candida species.
Lo, H. J., Ya, H., & Ho, M. (2001) · PubMed · Cited by 30
Deak, E., Etienne, K. A., Lockhart, S. R., Gade, L., Chiller, T., & Balajee, S. A. (2010) · Canadian Journal of Microbiology · doi:10.1139/w10-003 · Cited by 29 · cited 2×
“Isolates were identified using a Luminex assay or DNA sequencing of the D1-D2 subunit of the 28S recombinant DNA [15].”
Self-citationKaufman, D. A. (2008) · PEDIATRICS · doi:10.1542/peds.2008-1837 · Cited by 24 · cited 3×
“Prophylaxis with fluconazole in high-risk patients, such as neonates, has been shown to decrease risk of disease [21, 25–29].”
Skovbjerg, S., Welinder‐Olsson, C., Kondori, N., Kjellin, E., Nowrouzian, F. L., Wold, A. E., Stockelberg, D., Larsson, P., & Wennerås, C. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02796.x · Cited by 22
Detection of Candida Mannoproteinemia in Patients with Neutropenic Enterocolitis
Micozzi, A., Cartoni, C., Bernardis, F. D., Cassone, A., Martino, P., & Girmenia, C. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050226 · Cited by 21
Evaluation of Mycology Laboratory Proficiency Testing
Reilly, A. A., Salkin, I. F., McGinnis, M. R., Gromadzki, S., Pasarell, L., Kemna, M. E., Higgins, N., & Salfinger, M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.7.2297-2305.1999 · Cited by 21
Mootsikapun, P., Hsueh, P.-R., Talwar, D., Co, V. M., Rajadhyaksha, V., & Ong, M.-L. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-219 · Cited by 20 · cited 4×
“tropicalis candidemia was observed in other Asian countries as well [24].”
InfluentialDiagnostics of fungal infections in the Nordic countries: We still need to improve!
Arendrup, M. C., Chryssanthou, E., Gaustad, P., Koskela, M., Sandven, P., & Fernandez, V. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540601071859 · Cited by 20
Ljungman, P. T., Döbeln, L. V., Ringholm, L., Lewensohn‐Fuchs, I., Klingspor, L., Sparrelid, E., & Bouvet, E. (2005) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2019.12063271 · Cited by 19
Sakai, T., Ikegami, K., Yoshinaga, E., Uesugi-Hayakawa, R., & Wakizaka, A. (2000) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.190.119 · Cited by 17
Hurley, R. (1966) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700920240 · Cited by 16
Ribeiro, P., Costa, F., Monteiro, A., Caldas, J., da Silva, M. P., Ferreira, G., Veiga, J., Sousa, M. O., Viegas, M. P., Santos, E., et al. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-005-0903-7 · Cited by 15
Detection and identification of Candida sp. by PCR in candidemia diagnosis
Khlif, M., Sellami, H., Sellami, A., Makni, F., Cheikhrouhou, F., Chelly, H., Bouaziz, M., & Ayadi, M. A. (2007) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2007.10.001 · Cited by 13
Mayer, J., Kovařík, A., Vorlíček, J., Číhalová, J., & Kubálek, V. (1998) · Mycoses · doi:10.1111/j.1439-0507.1998.tb00708.x · Cited by 9
Fungal Infection among Patients with Some Hematopoietic Disorders.
Selim, H. S., Hammouda, A. F., Sadek, N. A., Ahmed, M. A., & Al-kadassy, A. M. (2006) · PubMed · Cited by 8
Research works printed but not linked: 2
- 1992, Chest, 10, 1644
- 2011, MMWR. Morbidity and mortality weekly report, 60, 243
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
“tropicalis is generally susceptible to fluconazole [103], and prophylaxis with this agent has been associated with a decrease in the incidence of C.”
BackgroundMultidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Epidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610
Chowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577
Metadata
- Authors
- Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M.
- Affiliations
- Centers for Disease Control and Prevention (US)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-14
- Volume
- 55
- Issue
- 10
- Pages
- 1352-1361
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2157512355
- Cited by
- 366
- References
- 138
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 17 · 2023: 16 · 2022: 23 · 2021: 32 · 2020: 35 · 2019: 21 · 2018: 42 · 2017: 35 · 2016: 28 · 2015: 44 · 2014: 33 · 2013: 19 · 2012: 2
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, candidemia incidence, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, multidrug resistance, infants, older adults, epidemiological trends, antifungal prophylaxis, infection control, catheter-related infection, Atlanta, Baltimore
- MeSH terms
- Adolescent, Adult, Aged, Antifungal Agents, Candida, Child, Child, Preschool, Female, Georgia, Humans, Infant, Male, Middle Aged, Population Surveillance, Prospective Studies, Baltimore, Incidence, Drug Resistance, Fungal, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.